Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties

Protein Engineering, Design and Selection

Volumn 25, Issue 10, 2012, Pages 551-559

  Castoldi, R ^a   Jucknischke, U ^a   Pradel, L P ^a   Arnold, E ^a   Klein, C ^b   Scheiblich, S ^a   Niederfellner, G ^a   Sustmann, C ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b Roche Glycart AG   (Switzerland)

Author keywords

ITC; receptor tyrosine kinase; SPR; therapeutic antibodies; trispecific antibodies

Indexed keywords

ANTIGEN-BINDING; CANCER THERAPY; CELL SURFACES; CELLULAR GROWTH; COOPERATIVE BINDING; DRUG EFFICACY; FUTURE APPLICATIONS; FUTURE DESIGNS; ISOTHERMAL TITRATION CALORIMETRY; ITC; KINETIC PROFILES; MOLECULAR CHARACTERIZATION; QUANTITATIVE ASSESSMENTS; RECEPTOR TYROSINE KINASE; RESISTANCE MECHANISMS; SPR; THERAPEUTIC ANTIBODIES; TUMOR BIOLOGY;

AMINO ACIDS; ANTIGENS; BINDING ENERGY; BIOCHEMISTRY; PHOSPHORYLATION; SURFACE PLASMON RESONANCE;

ANTIBODIES;

EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; FC RECEPTOR IIIA; SCATTER FACTOR RECEPTOR; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; CELL GROWTH; CELL PROLIFERATION; FLUORESCENCE ACTIVATED CELL SORTING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INHIBITION KINETICS; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; STEADY STATE; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; CELL LINE; CELL PROLIFERATION; CLONING, MOLECULAR; HUMANS; MODELS, MOLECULAR; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; RECEPTOR, IGF TYPE 1;

EID: 84866993578     PISSN: 17410126     EISSN: 17410134     Source Type: Journal    
DOI: 10.1093/protein/gzs048     Document Type: Article

References (30)

1. An, Z. (2010) Protein Cell, 1, 319-330.
2. Atwell, S., Ridgway, J.B., Wells, J.A., et al. (1997) J. Mol. Biol., 270, 26-35.
3. Bonanno, L., Jirillo, A. and Favaretto, A. (2011) Curr. Drug Targets, 12, 922-933.
4. Bossenmaier, B., Dimoudis, N., Friess, T., et al. (2011) WO 2011/076683. http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011076683&recNum= 1 &maxRec=1&office=&prevFilter=&sortOption=&queryString= 11076683& tab=PCT+Biblio.
5. Chames, P. and Baty, B. (2009a) Curr. Opin. Drug Discov. Devel., 12, 276-283.
6. Chames, P. and Baty, D. (2009b) MAbs, 1, 539-547.
7. Dennis, M.S., Billeci, K., Young, J., et al. (2007) US 2007/0092520 A1 .
8. Filpula, D. (2007) Biomol. Eng., 24, 201-215.
9. Hendrickson, A.W. and Haluska, P. (2009) Curr. Opin. Investig. Drugs, 10, 1032-1040.
10. Hynes, N.E. and Lane, H.A. (2005) Nat. Rev. Cancer, 5, 341-354.
11. Hynes, N.E. and MacDonald, G. (2009) Curr. Opin. Cell Biol., 21, 177-184.
12. Karamouzis, M.V., Konstantinopoulos, P.A. and Papavassiliou, A.G. (2009) Lancet Oncol., 10, 709-717.
13. Kontermann, R.E. (2010) Curr. Opin. Mol. Ther., 12, 176-183.
14. Kuenkele, K.P., Graus, Y., Kopetzki, E., et al. (2005) WO 2005/005635 A3. http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2005005635& recNum=1&maxRec=1&office=&prevFilter=&sortOption= &queryString= WO05005635&tab=PCT+Biblio.
15. Mansi, L., Thiery-Vuillemin, A., Nguyen, T., et al. (2010) Expert Opin. Drug Saf., 9, 301-317.
16. Metz, S., Haas, A.K., Daub, K., et al. (2011) Proc. Natl Acad. Sci. USA, 108, 8194-8199.
17. Nielsen, U.B., Huhalov, A., et al. (2008) 31st San Antonio Breast Cancer Symposium. http://www.mindcull.com/data/no/sabcs-2008-san-antoniobreast-cancer- symposium/p:64/r:10/.
18. Nieri, P., Donadio, E., Rossi, S., et al. (2009) Curr. Med. Chem., 16, 753-779.
19. Nimmerjahn, F. and Ravetch, J.V. (2008) Nat. Rev. Immunol., 8, 34-47.
20. Pillay, V., Allaf, L., Wilding, A.L., et al. (2009) Neoplasia, 11, 448-458.
21. Pivot, X., Bedairia, N., Thiery-Vuillemin, A., et al. (2011) Anticancer Drugs, 22, 701-710.
22. Ridgway, J.B., Presta, L.G., Carter, P., et al. (1996) Protein Eng., 9, 617-621.
23. Roopenian, D.C. and Akilesh, S. (2007) Nat. Rev. Immunol., 7, 715-725.
24. Schaefer, G., Haber, L., Crocker, L.M., et al. (2011) Cancer Cell, 20, 472-486.
25. Seimetz, D., Lindhofer, H., et al. (2010) Canc. Treat. Rev., 36, 458-467.
26. Thakur, A. and Lum, L.G. (2010) Curr. Opin. Mol. Ther., 12, 340-349.
27. Umana, P. and Mossner, E. (2011) WO 2006/082515. http://patentscope.wipo. int/search/en/detail.jsf?docId=WO2006082515&recNum=1&docAn= IB2006000238&queryString=FP:(WO06082515)&maxRec=1.
28. Van der Veeken, J., Oliveira, S., Schiffelers, R.M., et al. (2009) Curr. Cancer Drug Targets, 9, 748-760.
29. Vieth, M., Sutherland, J.J., Robertson, D.H., et al. (2005) Drug Discov Today, 10, 839-846.
30. Yarden, Y. and Sliwkowski, M.X. (2001) Nat. Rev. Mol. Cell Biol., 2, 127-137.